Microbiota Dynamics in Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short- and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT.

[1]  P. Gajer,et al.  Vaginal microbiome of reproductive-age women , 2010, Proceedings of the National Academy of Sciences.

[2]  Wolfgang Ludwig,et al.  Revised road map to the phylum Firmicutes , 2015 .

[3]  J. Pohl Clostridium difficile infection and proton pump inhibitors , 2012, Current opinion in pediatrics.

[4]  T. Borody,et al.  Fecal microbiota transplantation and emerging applications , 2012, Nature Reviews Gastroenterology &Hepatology.

[5]  David R. Riley,et al.  CloVR: A virtual machine for automated and portable sequence analysis from the desktop using cloud computing , 2011, BMC Bioinformatics.

[6]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[7]  J. Bartlett,et al.  Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  W. D. de Vos,et al.  Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. , 2004, International journal of systematic and evolutionary microbiology.

[9]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[10]  J. Jansson,et al.  Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea , 2009, Journal of clinical gastroenterology.

[11]  Vincent B. Young,et al.  Suppression of Clostridium difficile in the Gastrointestinal Tracts of Germfree Mice Inoculated with a Murine Isolate from the Family Lachnospiraceae , 2012, Infection and Immunity.

[12]  John D Lambris,et al.  Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. , 2011, Cell host & microbe.

[13]  W. M. Vos,et al.  Microbes inside—from diversity to function: the case of Akkermansia , 2012, The ISME Journal.

[14]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[15]  D. Musher,et al.  Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. , 2007, The Journal of antimicrobial chemotherapy.

[16]  D. Relman,et al.  Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation , 2010, Proceedings of the National Academy of Sciences.

[17]  R Balfour Sartor,et al.  Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.

[18]  J. Castilla,et al.  Challenges in the Quest for Keystones , 1996 .

[19]  A. Berstad,et al.  [Clostridium difficile-associated diarrhea treated with homologous feces]. , 1998, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[20]  G. Gloor,et al.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut , 2013, Microbiome.

[21]  G. Tannock,et al.  Nucleic acid-based methods to assess the composition and function of the bowel microbiota. , 2012, Gastroenterology clinics of North America.

[22]  W. Petritsch,et al.  Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[23]  W. Roediger Utilization of nutrients by isolated epithelial cells of the rat colon. , 1982, Gastroenterology.

[24]  D. Gerding,et al.  Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  D. Gerding,et al.  Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. , 2009, Anaerobe.

[26]  V. Mai,et al.  Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.

[27]  Luying Peng,et al.  Effects of Butyrate on Intestinal Barrier Function in a Caco-2 Cell Monolayer Model of Intestinal Barrier , 2007, Pediatric Research.

[28]  C. Surawicz,et al.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  L. Brandt,et al.  Clostridium difficile Infection and Inflammatory Bowel Disease , 2013, Journal of clinical gastroenterology.

[30]  Matthew J. Hamilton,et al.  High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria , 2013, Gut microbes.

[31]  E. van Nood,et al.  Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? , 2013, Best practice & research. Clinical gastroenterology.

[32]  K. Garey,et al.  Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study , 2009, Journal of clinical gastroenterology.

[33]  S. Maroo,et al.  Recurrent clostridium difficile. , 2006, Gastroenterology.

[34]  S. O'keefe Tube feeding, the microbiota, and Clostridium difficile infection. , 2010, World journal of gastroenterology.

[35]  Taane G. Clark,et al.  Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice , 2012, PLoS pathogens.

[36]  J. Rombeau,et al.  Parenteral nutrition supplemented with short-chain fatty acids: effect on the small-bowel mucosa in normal rats. , 1990, The American journal of clinical nutrition.

[37]  J. Bakken,et al.  Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  A. Manges,et al.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  James R. White,et al.  CloVR-16S: Phylogenetic microbial community composition analysis based on 16S ribosomal RNA amplicon sequencing – standard operating procedure, version 1.0 , 2011 .

[40]  Martin Hartmann,et al.  Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.

[41]  J. Tiedje,et al.  Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy , 2007, Applied and Environmental Microbiology.

[42]  D. Anderson,et al.  Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals , 2011, Infection Control & Hospital Epidemiology.

[43]  R. Xavier,et al.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 , 2009, Nature.

[44]  G. Garrity Bergey’s Manual® of Systematic Bacteriology , 2012, Springer New York.

[45]  T. Stukel,et al.  Reduction in Clostridium difficile Infection Rates after Mandatory Hospital Public Reporting: Findings from a Longitudinal Cohort Study in Canada , 2012, PLoS medicine.

[46]  U. Navaneethan,et al.  Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. , 2010, World journal of gastroenterology.

[47]  S. Routhier,et al.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  B. Ebenman,et al.  Using community viability analysis to identify fragile systems and keystone species. , 2005, Trends in ecology & evolution.

[49]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[50]  J. Bakken,et al.  Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Paramvir S. Dehal,et al.  FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.

[52]  Gerhard G. Thallinger,et al.  Alterations in the Colonic Microbiota in Response to Osmotic Diarrhea , 2013, PloS one.

[53]  J. Silva,et al.  Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. , 1987, Journal of clinical gastroenterology.

[54]  T. Lamont,et al.  Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. , 2010, Journal of pediatric gastroenterology and nutrition.

[55]  K. Whelan,et al.  Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[56]  J. Bartlett,et al.  Clinical practice. Antibiotic-associated diarrhea. , 2002, New England Journal of Medicine.

[57]  Gaurav Agrawal,et al.  Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions , 2013, Current Gastroenterology Reports.

[58]  Wolfgang Ludwig,et al.  Revised road map to the phylum Firmicutes , 2015 .

[59]  Emma Allen-Vercoe,et al.  Toward an Understanding of Changes in Diversity Associated with Fecal Microbiome Transplantation Based on 16S rRNA Gene Deep Sequencing , 2012, mBio.

[60]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[61]  N. Fairweather,et al.  Antibiotic Treatment of Clostridium difficile Carrier Mice Triggers a Supershedder State, Spore-Mediated Transmission, and Severe Disease in Immunocompromised Hosts , 2009, Infection and Immunity.

[62]  E. Zoetendal,et al.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.

[63]  Mihai Pop,et al.  Statistical Methods for Detecting Differentially Abundant Features in Clinical Metagenomic Samples , 2009, PLoS Comput. Biol..

[64]  Bernard Zenko,et al.  Gut Microbiota Patterns Associated with Colonization of Different Clostridium difficile Ribotypes , 2013, PloS one.

[65]  B. Sheppard,et al.  Clostridium difficile colitis: an increasing hospital-acquired illness. , 1995, American journal of surgery.

[66]  A. Berman Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. , 2007, Journal of clinical gastroenterology.

[67]  S. Woods,et al.  Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. , 2003, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.

[68]  Rob Knight,et al.  UCHIME improves sensitivity and speed of chimera detection , 2011, Bioinform..

[69]  Neil Stollman,et al.  Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.

[70]  M. Taljaard,et al.  The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital , 2012, Canadian Medical Association Journal.